Technology transfer in biologics is one of the most sensitive stages in the path from development to manufacturing. Small gaps in process understanding, analytics or execution can create delays, increase variability and add pressure just when programs need greater control. Explore four of the most common risks in biologics tech transfer, and how CDMOs help reduce them to support GMP readiness, comparability and a smoother path to commercial manufacturing.

One of the biggest transfer risks appears when the receiving team has the documentation, but not the full context behind it. Batch records, methods and parameters may all be available, yet key decisions, previous observations or process sensitivities remain unclear.

In biologics, that missing context matters. A step that seemed routine during development may become critical at a different site or scale. The goal is to ensure the receiving team understands what the process is and why it works the way it does. Experienced CDMOs help close that gap by turning process history into usable knowledge and aligning teams early around what truly drives performance.

A process that performs well at lab or pilot scale may respond differently once it moves into a manufacturing environment. Changes in mixing, oxygen transfer, filtration or hold times can affect consistency and product quality, even when the overall process appears unchanged.

Scale-up, then, is not simply a larger version of development. It is the point where process robustness is tested under new conditions. CDMOs reduce this risk by assessing facility fit early, identifying scale-sensitive steps and using engineering runs or similar activities to understand where adjustments may be needed before GMP execution.

A transfer can only be considered successful if the receiving site is able to assess the product with confidence. When analytical methods are not fully aligned, it becomes harder to confirm comparability, support release testing or investigate deviations in a reliable way.

For that reason, analytical method transfer plays a central role in biologics manufacturing. Strong CDMO support includes early method alignment, clearly defined acceptance criteria and the analytical expertise needed to generate data that teams can trust throughout development and commercial manufacturing.

Some of the most damaging transfer problems do not come from the process itself, but from the way teams interact. Development, manufacturing, analytical, quality and project management functions often work on different timelines and with different priorities, especially when several organizations are involved.

When coordination is weak, delays tend to appear at the worst moments: during reviews, before execution or when decisions depend on several functions moving at the same pace. This is why effective tech transfer also depends on governance, planning and communication. A structured CDMO model helps connect those moving parts and reduce friction across the project.

In biologics, tech transfer depends on more than manufacturing capacity alone. Process understanding, scale-up readiness, analytical alignment and cross-functional coordination all shape whether a transfer moves forward smoothly or becomes a source of delay and rework.

This is why companies evaluating a CDMO partner often look beyond infrastructure. They also assess how well that partner can identify transfer risks early, manage them in a structured way and support a more reliable path from development to GMP and commercial manufacturing.

At mAbxience, this same integrated approach guides how we support biologics tech transfer projects, with a focus on clarity, control and quality throughout the process.